EUVIMEDEUVIMED entdecken
VergleichsstudieFall-Kontroll-StudieOpen Access · CC BY 4.0

Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study

Layan Sukik iD, Pradipta Paul iD, Houssein H Ayoub iD, Peter Coyle, Patrick Tang iD, Mohammad R Hasan, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko iD, Anvar Hassan Kaleeckal und 11 weitere

International Journal of Epidemiology · 2026

DOI: 10.1093/ije/dyag210 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Epidemiology, 2026. Verfasst von Layan Sukik und 22 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. Hauptthemen laut MEDLINE: Vaccine Efficacy, COVID-19, COVID-19 Vaccines, Epidemiologic Research Design. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar Research Development and Innovation Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Observational studies are central to assessing vaccine effectiveness and informing public health policy. The two most common designs are test-negative case-control and cohort studies, yet direct comparisons of their performance using the same population, data sources, and analytic strategies remain rare. This study compares these two designs within a national population using harmonized analytic approaches.

Methods

Nationwide, matched test-negative case-control and retrospective cohort studies were conducted in Qatar between 1 January 2021 and 18 December 2021 to assess the effectiveness of the coronavirus disease (COVID-19) primary series of BNT162b2 and mRNA-1273 against any severe acute respiratory syndrome coronavirus 2 infection, symptomatic infection, and severe COVID-19.

Results

In the test-negative design, BNT162b2 effectiveness was 71.0% [95% confidence interval (CI): 70.1–71.9] against any infection, 75.6% (95% CI: 74.2–77.0) against symptomatic infection, and 96.3% (95% CI: 95.2–97.2) against severe COVID-19. In the cohort design, after adjustment for testing rate, corresponding effectiveness was 78.0% (95% CI: 77.1–78.9), 81.2% (95% CI: 79.8–82.5), and 98.0% (95% CI: 96.6–98.8), respectively. Both designs demonstrated similar, rapid, and largely linear waning of effectiveness in both magnitude and pattern. Test-negative design estimates lay between cohort estimates with and without adjustment for testing rate. Similar results were observed for mRNA-1273.

Conclusions

Both designs yielded consistent effectiveness estimates across vaccines and clinically relevant outcomes, with only modest differences related to handling of health-seeking behavior. These findings demonstrate that, when rigorously implemented using quality data and harmonized analytic strategies, both designs produce comparable effectiveness estimates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine EfficacyCOVID-19COVID-19 VaccinesEpidemiologic Research DesignHumansCase-Control StudiesRetrospective Studies2019-nCoV Vaccine mRNA-1273FemaleBNT162 VaccineMaleQatarAdultSARS-CoV-2Middle AgedAgedAdolescentYoung Adult

Stichwörter der Autor:innen

SARS-CoV-2biasefficacyinfectionmRNA

Substanzen

2019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 Vaccines

Autor:innen und Institutionen

  • Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Mathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University, Doha, Qatar.
  • Hamad Medical Corporation, Doha, Qatar.
  • Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

ORCID-Profile: Layan Sukik, Pradipta Paul, Houssein H Ayoub, Patrick Tang, Andrew Jeremijenko, Gheyath K Nasrallah, Hiam Chemaitelly, Laith J Abu-Raddad

Förderung

  • Qatar Research Development and Innovation Council

Zitieren

APA

Sukik, L., Paul, P., Ayoub, H. H., Coyle, P., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., …, & Abu-Raddad, L. J. (2026). Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyag210

Vancouver

Sukik L, Paul P, Ayoub HH, Coyle P, Tang P, Hasan MR, et al. Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study. International Journal of Epidemiology. 2026. doi:10.1093/ije/dyag210

BibTeX
@article{Sukik2026,
  author = {Sukik, Layan and Paul, Pradipta and Ayoub, Houssein H and Coyle, Peter and Tang, Patrick and Hasan, Mohammad R and Yassine, Hadi M and Thani, Asmaa A Al and Al-Kanaani, Zaina and Al-Kuwari, Einas and Jeremijenko, Andrew and Kaleeckal, Anvar Hassan and Latif, Ali Nizar and Shaik, Riyazuddin Mohammad and Abdul-Rahim, Hanan F and Nasrallah, Gheyath K and Al-Kuwari, Mohamed Ghaith and Butt, Adeel A and Al-Romaihi, Hamad Eid and Al-Thani, Mohamed H and Al-Khal, Abdullatif and Chemaitelly, Hiam and Abu-Raddad, Laith J},
  title = {Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study},
  journal = {International Journal of Epidemiology},
  year = {2026},
  doi = {10.1093/ije/dyag210}
}
Kostenlos starten →